Albert David Ltd.

ALBERTDAVDNSEHealthcarePharmaceuticals & DrugsSmall Cap

₹711.15

▼ 0.11%

—

Composite

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

www.albertdavidindia.comSector: HealthcareIndustry: Pharmaceuticals & Drugs

Q-DITS fundamental score

—Composite

Growth

Profitability

Valuation

Quality

Solvency

Earnings

Key metrics

MCap

₹408 Cr

TTM PE

26.9x

Industry PE

38.2x

TTM EPS

₹-2.62

Book Value

₹686.04

Face Value

₹10

Div Yield

0.7%

PEG

—

1.2x

ROE

4.4%

ROCE

6.5%

EBITDA mgn

8.8%

D/E

0.03

Int. Cover

47.1x

Curr. Ratio

2.15x

EPS

₹30.14

Growth — CAGR across horizons

Metric	1Y	3Y	5Y	10Y
Net Sales	-3.5%	-0.8%	6.2%	-0%
EBITDA	80.6%	-50.2%	-22.2%	-15.9%
Net Profit	-108.7%	—	—	—

Score snapshot

Piotroski

1/9

Altman Z

2.12

Quality

50.8

Growth

Valuation

—

Earn. Qual

PEAD

SURGE

Revenue, profitability & returns

Revenue & Net Profit (₹ Cr)

RevenueNet Profit

Margins (%)

EBITDA%PAT%

Return ratios (%)

ROEROCEROA

Annual financials — last 10 years

Tap any row to see its trend

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Trend
›RevenueCr	323	295	290	317	321	247	314	342	362	346	↓
›EBITDACr	74	34	25	51	38	36	57	60	105	33	↓
›EBITDA margin	10%	11.1%	8.2%	15.2%	11.1%	14%	17.2%	16.6%	27.3%	8.8%	↓
›Net profitCr	48	16	10	27	19	22	35	36	75	17	↓
›PAT margin	14.4%	5.2%	3.2%	8%	5.7%	8.5%	10.7%	10%	19.7%	4.6%	↓
›EPS₹	₹84.1	₹27.96	₹17.24	₹46.68	₹33.59	₹38.8	₹61.78	₹63.38	₹132.15	₹30.14	↓
›Revenue growth	0.3%	-8.5%	-1.7%	9.3%	1.1%	-22.9%	26.7%	8.9%	6.1%	-4.6%	↓
›PAT growth	250.3%	-66.8%	-38.3%	170.7%	-28%	15.5%	59.2%	2.6%	108.5%	-77.2%	↓
›ROE	41.8%	10%	5.3%	13.4%	8.8%	9.5%	13.5%	12.2%	21.7%	4.4%	↓
›ROCE	46.5%	14.3%	7.9%	20.6%	13.7%	12%	18.1%	17.1%	27.9%	6.5%	↓
›ROA	19.4%	5.2%	2.8%	7.2%	5%	5.5%	8%	7.3%	13.5%	2.8%	↓
›P/E	3.6x	11.4x	21.1x	8.4x	9.6x	9.7x	8.6x	8.1x	8.1x	26.9x	↑
›P/B	1.2x	1x	1.1x	1.1x	0.8x	0.9x	1.1x	0.9x	1.6x	1.2x	↓
›D/E	0.1	0.2	0.1	0	0	0	0	0	0	0	↑
›Current ratio	1.6x	1.5x	1.5x	1.8x	1.8x	2.1x	1.8x	2.1x	2.3x	2.1x	↓
›Interest cover	31.7x	29.4x	16.7x	50.8x	30.4x	36x	71.4x	87.9x	226.3x	47.1x	↓

Quarterly results

Tap any row to see its trend

Metric	2023-12	2024-03	2024-06	2024-09	2024-12	2025-03	2025-06	2025-09	2025-12	2026-03	Trend
›RevenueCr	88	89	89	98	83	75	71	87	90	86	↓
›Rev growth YoY	18.4%	9.4%	-2.8%	5.6%	-5.9%	-15.9%	-21%	-11.4%	8.2%	14.6%	↑
›EBITDACr	8	10	1	6	1	-5	-11	3	11	3	↓
›EBITDA margin	9.5%	10.7%	1%	6.3%	0.8%	-6.3%	-15.1%	2.9%	12%	3.2%	↓
›Net profitCr	19	13	19	18	-9	-10	8	-3	15	-21	↓
›PAT growth YoY	77.5%	245.8%	-19.8%	-11%	-150.2%	-180%	-57.9%	-118.3%	263%	-107.5%	↓
›EPS₹	₹32.8	₹22.62	₹33.02	₹31.66	₹-16.45	₹-18.1	₹13.91	₹-5.79	₹26.81	₹-37.56	↓

Balance sheet — last 10 years (₹ Cr)

Tap any row to see its trend

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Trend
›Shareholders' equityCr	183	186	210	223	244	279	312	383	392	392	↓
›ReservesCr	177	180	205	217	239	274	306	377	387	386	↓
›Total borrowingsCr	0	0	0	0	0	0	0	0	0	0	—
›InvestmentsCr	63	79	123	135	157	216	202	291	299	0	↓
›Total assetsCr	196	205	229	250	269	294	324	396	401	519	↑
›Current assetsCr	234	243	263	268	278	327	394	478	467	374	↓
›Current liabilitiesCr	159	160	145	149	135	181	189	205	217	115	↓
›Trade payablesCr	27	32	30	38	25	30	32	34	38	33	↓
›Gross blockCr	221	192	192	212	212	223	222	231	251	99	↓

Cash flow statement (₹ Cr)

Tap any row to see its trend

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Trend
›Operating CF (CFO)Cr	20	30	32	30	37	40	11	46	-28	-8	↑
›Investing CF (CFI)Cr	-37	-11	-19	-20	-39	-40	-5	-33	23	-4	↓
›Financing CF (CFF)Cr	7	-5	-17	-10	-2	-2	-6	-8	0	12	↑
›Net cash changeCr	-10	14	-4	-0	-4	-1	-1	4	-5	-0	↑
›Closing cashCr	-4	11	6	6	3	2	1	5	0	0	↓

Cash flow components

CFO · CFI · CFF (₹ Cr)

CFOCFICFF

Q-DITS scorecard

Composite score

—

Quality (25%)50.8

Growth (25%)0

Valuation (20%)—

Piotroski (15%)11

Earnings Quality (10%)0

Momentum (5%)—

Weighted blend, rescaled to the components available for this stock.

Piotroski F-Score

1/9

✓ROA positiveROA 2.8%

✗CFO positiveCFO ₹-7.66 Cr

✗ROA improving13.51% → 2.8%

✗CFO > PAT (low accruals)CFO -7.66 vs PAT 17.2

✗Leverage decreasedD/E 0.01 → 0.03

✗Liquidity improvedCR 2.33 → 2.15

✗No share dilutionEPS 132.15 → 30.14

✗Margin improvedEBITDA mgn 27.26% → 8.82%

✗Asset turnover upAsset TO 0.69 → 0.6

Altman Z-Scoregrey

2.12

0.499

0.743

0.05

0.754

0.666

>2.9 safe · 1.23–2.9 grey · <1.23 distress

Quality

50.8/100

ROE

4.4%

ROCE

6.5%

Margin

4.6%

Debt

Int. cover

47.1x

Growth

0/100

Revenue 3Y

-0.8%

Profit 3Y

-108.7%

EPS

-77.2%

Valuation

N/A

—

EV/EBITDA

—

Earnings quality

0/100

CFO₹-8 Cr

PAT₹17 Cr

Accrual ratio0.048

CFO/PAT-0.45x

PEAD · SURGE

0 / 0

Revenue SUE1.33

EPS SUE-2.54

Latest quarter2026-03

Rev growth YoY14.6%

Shareholding pattern

Promoter62.2%

FII/FPI0.6%

DII1.7%

Public37.8%

Tap any row to see its trend

Metric	2024-03	2024-06	2024-09	2024-12	2025-03	2025-06	2025-09	2025-12	2026-03	Trend
›Promoter	62.1%	62.1%	62.1%	62.1%	62.2%	62.2%	62.2%	62.2%	62.2%	—
›FII / FPI	1%	0.8%	0.9%	0.9%	1%	0.8%	0.6%	0.6%	0.6%	↓
›DII	1.7%	1.7%	1.6%	1.6%	1.6%	1.7%	1.7%	1.7%	1.7%	↑
›Public / Retail	37.9%	37.9%	37.9%	37.9%	37.8%	37.8%	37.8%	37.8%	37.8%	—
›Promoter pledge	0%	0%	0%	0%	0%	0%	0%	0%	0%	—

Documents & filings

Loading documents…

Peer comparison

Company	MCap (Cr)	Revenue	PAT	PE	PB	ROE%	ROCE%	D/E
Sun Pharmaceutical Industries Ltd.	4,40,794	58,462	11,565	38.4x	5.3x	16.2	19.9	0.03
Divi's Laboratories Ltd.	1,78,956	10,560	2,568	69.7x	10.7x	15.4	20.5	0
Torrent Pharmaceuticals Ltd.	1,49,820	13,980	2,138	69.3x	17.9x	26.8	19.3	1.76
Cipla Ltd.	1,09,370	28,163	3,870	28.2x	3.2x	11.8	16	0.01
Lupin Ltd.	1,07,537	27,958	5,355	20.2x	4.8x	21.1	22	0.3
Zydus Lifesciences Ltd.	1,06,823	27,148	5,026	21.2x	4x	21.1	26.1	0.13
Dr. Reddy's Laboratories Ltd.	1,06,133	33,700	4,144	25.3x	2.8x	18.6	23.3	0.14